Trial Profile
A phase I, open-labelled study investigating liposomal recombinant human Cu/Zn-superoxide dismutase (Lipoxysan) for the treatment of inflammation-induced impairment of vascular reactivity
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Feb 2016
Price :
$35
*
At a glance
- Drugs Superoxide dismutase (Primary)
- Indications Inflammation
- Focus Therapeutic Use
- 19 Feb 2016 New trial record